TRS005

DRUG2 trials

Sponsors

Zhejiang Teruisi Pharmaceutical Inc.

Conditions

CD20-positive Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)

Phase 1

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

Not yet recruitingNCT07035379

Zhejiang Teruisi Pharmaceutical Inc.Diffuse Large B-Cell Lymphoma (DLBCL)

Start: 2025-09-01End: 2028-09-01Target: 66Updated: 2025-08-22

Phase 2

A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.

Not yet recruitingNCT06886139

Zhejiang Teruisi Pharmaceutical Inc.CD20-positive Diffuse Large B-Cell Lymphoma

Start: 2025-09-30End: 2027-09-30Target: 139Updated: 2025-08-22